An Introduction to Paediatric Neurology
Paediatric neurology, relating to children from birth to young adulthood, is a challenging area of medicine requiring collaboration between the paediatrician, adult neurologist and specialist paediatric neurologist. Advancing treatments in disorders such as epilepsy, brain and spinal tumours, neuromuscular disorders, and inborn errors of metabolism, show promise for the future of these patients.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Paediatric Neurology Content
Addressing unmet needs to improve outcomes for people with epilepsy
Keep up to date on the latest developments by watching this webinar discussing key issues in the treatment and management of severe epilepsy, focussing on: The key unmet medical needs that still exist for people with severe epilepsy. How the latest clinical trial results support emerging therapeutic options to address these unmet needs. Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy. Part 1: Watch the webinar with three internationally renowned experts discussing key issues in the treatment and management of severe epilepsy Watch Now Part 2: Watch the interview providing the highlights of the webinar Watch Now
- Assess the main diagnostic approaches in epilepsy and the challenges that remain in the management and monitoring of the disease, particularly during the COVID-19 pandemic
- Recognize the key medical unmet needs that remain for people with epilepsy, especially with conditions that are often refractory to conventional anti-epileptic drugs, such as encephalopathic epilepsies
- Describe recent therapeutic developments in epilepsy, evaluate the supporting clinical evidence, and appreciate how they might impact quality of life beyond symptom control
Key developments in the diagnosis, treatment and understanding of childhood-onset, treatment-resistant epilepsies with Dr Antonietta Coppola & Dr Angel Aledo-Serrano
Watch this two-part activity discussing diagnostic and therapeutic advances in the field of childhood-onset treatment-resistant epilepsy from AES 2020 Part 1: Watch internationally renowned expert Dr Antonietta Coppola review key data from the conference focussing on genetic diagnosis and treatments Watch Now Part 2: Choose from two leading experts who discuss how data presented at the AES 2020 may affect daily practice Select An Interview
- Recognise the unmet needs and challenges that remain for people living with childhood-onset, treatment-resistant epilepsies.
- Understand the challenges that remain in the management and monitoring of the childhood-onset epilepsies, and be aware of the key diagnostic advances presented at AES 2020.
- Describe the key therapeutic developments for childhood-onset, treatment-resistant epilepsies presented at AES 2020.
Taking the next steps to improve patient outcomes in SMA: Early diagnosis and treatment
Learn more about the early diagnosis and treatment of spinal muscular atrophy (SMA) in this discussion between three internationally renowned experts. For subtitles in Spanish and Brazilian Portuguese, please click [CC] on the video player below.
- Recall the outcomes associated with early treatment initiation for patients with SMA
- Discuss strategies for diagnosing SMA as early as possible
- Describe the latest research findings for biomarkers in SMA
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Kelly Knupp, AES 2020 – Fenfluramine for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]
Cannabidiol Oral Solution – A New Class of Antiseizure Medication
European Neurological Review. 2020;15(1):19–26 DOI: https://doi.org/10.17925/ENR.2020.15.1.19
Epilepsy is one of the most common neurological disorders, affecting around 70 million people worldwide.1,2 Its management is mainly symptomatic, and long-term seizure remission is achieved in most cases.3,4 One-third of patients, however, continue to experience seizures despite adequate treatment.5 Remarkably, the burden of refractory epilepsy has remained stable over the last decades despite increasing therapeutic resources, including […]
DSUK – Dravet Syndrome in the COVID-19 Pandemic – Webinar with Professor Helen Cross OBE
Video produced by and shared with kind authorisation of Dravet Syndrome UK (DSUK). Professor Helen Cross OBE is a globally-recognised authority on Dravet Syndrome and Chair of DSUK’s Medical Advisory Board. On Monday 30 March, she took part in a webinar for families registered with DSUK, presenting on COVID-19 and answering a range of questions. […]
Presentation, diagnosis and management of SMA: Multidisciplinary perspectives
Watch leading experts discuss the diagnosis and management of spinal muscular atrophy (SMA), including causes of diagnostic delay, emerging treatment approaches and the crucial role of the multidisciplinary team in the management of this disease. Dr Nancy Kuntz (Ann & Robert H. Lurie Children’s Hospital of Chicago) discusses the diagnosis of SMA, Dr Eduardo Tizzano (Hospital Vall d’Hebron, Barcelona) reviews clinical management and emerging therapeutic options, and Dr Oscar H. Mayer (The Children’s Hospital of Philadelphia) describes the crucial role of multidisciplinary management.
- Identify patients at risk of spinal muscular atrophy (SMA) through genetic screening and recognize early symptoms in the disease course
- Describe key trial and registry data (including antisense oligonucleotide and gene therapy) supporting improved treatment practice and outcomes in SMA patients
- Discuss roles within the multidisciplinary team (MDT) and impact of a standardized treatment approach across the MDT including utilization of guidelines and treatment innovations for SMA patients in clinical practice
Christopher Glisson, AAN 2019 – Updates in pediatric neuro-ophthalmology
Christopher Glisson (Mercy Health Hauenstein Neurosciences, Michigan, USA) kindly took the time to talk us on the topic of his update session at AAN on pediatric neuro-ophthalmology. Questions What are the particular challenges of paediatric as opposed to adult neuro-ophthalmology? (0:04) What are the most commonly seen optic neuropathies in childhood? (0:47) What is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!